Recent research from Japanese hospitals has confirmed that lecanemab is safe for most patients with early Alzheimer’s disease, with over 90% of participants able to continue treatment without experiencing strong side effects. A study of 2,672 patients across Japanese healthcare facilities found that at 28 weeks after treatment began, the vast majority tolerated the drug well, experiencing at most minor adverse effects that were manageable and often temporary.
This confirmation matters because lecanemab represents one of the first treatments shown to slow cognitive decline in early-stage Alzheimer’s disease, but like any medication, its safety profile needed careful monitoring in real-world settings beyond clinical trials. This article examines what recent research tells us about lecanemab’s safety, including data from both Japan and the United States, how long patients typically continue the treatment, what side effects actually occur and how often, and what the long-term outlook shows for people considering this therapy. We’ll also discuss who might be appropriate candidates and what limitations exist.
Table of Contents
- What the New Japanese Hospital Research Shows About Lecanemab Safety
- Real-World Treatment Persistence in the United States
- The Balance Between Safety and Cognitive Benefits
- Understanding Lecanemab’s Specific Side Effects
- Who Should Consider Lecanemab and Important Limitations
- What Extended Treatment Data Reveals About Safety
- The Evolving Evidence and What It Means for Patient Decisions
- Conclusion
What the New Japanese Hospital Research Shows About Lecanemab Safety
The March 2026 research presented by The Japan Times detailed outcomes from a substantial patient population—2,672 individuals treated across multiple hospital settings in Japan. The headline finding was straightforward: 90% or more of these patients were able to continue lecanemab treatment at 28 weeks without experiencing strong or disabling side effects. This matters because it translates clinical trial results into what actually happens when thousands of real patients, with varying health conditions and backgrounds, receive the drug in everyday medical practice.
The side effect profile was more granular than simply “safe or unsafe.” About 7.1% of patients experienced minor side effects, which included small amounts of bleeding—the most concerning but still manageable category. At the more serious end, 0.1% experienced serious side effects requiring intervention. A separate group—17% of patients—developed fever or headache, but these symptoms improved within days and did not require treatment discontinuation. This distribution suggests that while lecanemab does cause effects in a portion of patients, most effects are either absent, minor, or self-limiting.
Real-World Treatment Persistence in the United States
While the Japanese data shows what happens in the first few months, American healthcare data provides insight into longer-term persistence—whether patients continue treatment month after month and year after year. Data presented at the March 2026 AD/PD Congress from Eisai’s review of insurance claims in the United States showed that 78.4% of lecanemab-treated patients continued the medication at 18 months.
this declined gradually to 71.7% at 20 months and 67.3% at 24 months. The practical implication is important: while some patients do stop treatment—whether due to side effects, cost, inconvenience, or lack of perceived benefit—the majority stick with it for extended periods. However, this also reveals a limitation: one-third of patients have discontinued by two years, suggesting that lecanemab is not universally tolerable or effective enough for everyone to maintain long-term, and healthcare providers should monitor each patient’s individual response rather than assume everyone will continue indefinitely.
The Balance Between Safety and Cognitive Benefits
Lecanemab’s safety profile only matters in context—it’s valuable because the drug actually slows cognitive decline. The 2026 AD/PD Congress also presented extended follow-up data showing that patients who continued lecanemab experienced measurable cognitive benefits over years. At three years of treatment, patients showed a 1.01-point reduction in cognitive decline compared to the natural disease progression.
By four years, this benefit expanded to 1.75 points when compared to expected decline, or 2.17 points when benchmarked against a reference cohort from the BioFINDER study. These numbers may seem small, but in the context of Alzheimer’s disease—where a patient might otherwise lose several points of cognitive function annually—slowing that decline by 1-2 points over years represents meaningful preservation of memory and thinking ability. The safety data becomes most relevant when patients understand they’re receiving a medication that is both tolerable for most and actually provides cognitive benefit. A patient tolerating minor side effects for four years while preserving significantly more cognitive function than they would have otherwise has a different calculus than one experiencing side effects for no benefit.
Understanding Lecanemab’s Specific Side Effects
Lecanemab’s side effect profile includes several categories that deserve specific attention. The most commonly discussed is amyloid-related imaging abnormalities (ARIA)—changes visible on brain MRI that can include microhemorrhages (tiny bleeds) or microinfarcts (tiny areas of dead tissue). This is why the Japanese data noting 7.1% with minor bleeding is important—it reflects real-world experience with this risk. For context, ARIA occurred in clinical trials at higher rates in lecanemab-treated patients compared to placebo, but most cases were asymptomatic, meaning patients had no symptoms even when imaging showed changes.
Infusion reactions represent another safety consideration. Because lecanemab is delivered intravenously every two weeks, some patients experience reactions during or shortly after infusion—ranging from mild (flushing, itching) to more significant (fever, chills, shortness of breath). The data showing 17% experienced fever or headache likely captures some of these infusion-related effects. Most importantly, however, serious infusion reactions are uncommon, and medical staff can slow or temporarily halt infusions if reactions occur. This distinguishes lecanemab from medications where side effects might develop unpredictably or dangerously.
Who Should Consider Lecanemab and Important Limitations
Lecanemab is specifically approved for patients with mild cognitive impairment or mild dementia stage Alzheimer’s disease who have confirmed amyloid pathology in their brain (typically demonstrated by PET scan or spinal fluid testing). This limitation is crucial: the drug only works for a specific disease stage and only in patients with amyloid pathology. Someone with moderate or advanced dementia, or someone whose cognitive symptoms stem from causes other than Alzheimer’s amyloid, would not benefit and should not receive lecanemab.
Additionally, lecanemab requires regular infusions every two weeks indefinitely, which means patients need reliable access to an infusion center, transportation to appointments, and the ability to commit to ongoing medical monitoring. For some patients—particularly those in rural areas without local infusion capacity, those with severe mobility limitations, or those with unstable housing—the practical barriers exceed the medical benefits. This is a real limitation worth discussing with a doctor: lecanemab is not appropriate for everyone with early Alzheimer’s, even if their disease stage and amyloid status would otherwise qualify them.
What Extended Treatment Data Reveals About Safety
The fact that we now have data extending to three and four years of lecanemab treatment is itself reassuring—it means patients have continued long enough for longer-term safety patterns to emerge. The cognitive benefit data (1.75 to 2.17 points of decline reduction) specifically comes from patients who stayed in extended follow-up, which requires both that they tolerated the drug and that researchers could track them. If lecanemab created significant delayed safety concerns—progressive brain damage, accumulating side effects, or deteriorating function—we would expect to see higher discontinuation rates or worsening outcomes in this extended cohort.
Instead, the data suggests that lecanemab’s safety profile, while not risk-free, remains relatively stable over years. Patients who tolerate it initially and continue tend to maintain that tolerance and to experience cognitive preservation. However, this doesn’t mean safety is guaranteed for everyone or that new concerns will never emerge—long-term safety data is always evolving as more patients take medications for longer periods.
The Evolving Evidence and What It Means for Patient Decisions
The convergence of safety data from Japan and the United States in early 2026 represents a significant milestone in Alzheimer’s treatment. Rather than relying on a single clinical trial, healthcare providers and patients now have real-world evidence from thousands of people across different healthcare systems and geographies.
This consistency across settings strengthens confidence that the safety findings are robust and not artifacts of a single study population or setting. Looking forward, the next critical questions for lecanemab research involve identifying which patients benefit most, whether earlier treatment initiation improves outcomes further, and whether combining lecanemab with other emerging Alzheimer’s therapies might offer even greater cognitive preservation. For now, the 2026 safety data supports the conclusion that lecanemab is a treatment worth considering seriously for appropriate candidates—not a cure, not without side effect risks, but a medication that slows cognitive decline in early Alzheimer’s disease with a tolerability profile that allows most patients to continue long-term.
Conclusion
Recent research from Japanese hospitals involving 2,672 patients confirms that lecanemab is tolerable for the vast majority of people with early Alzheimer’s disease, with over 90% able to continue treatment without strong side effects at 28 weeks. Long-term U.S. data shows that roughly two-thirds of patients continue treatment at two years, and extended follow-up data demonstrates cognitive benefits that persist and accumulate over three to four years of therapy.
While lecanemab does carry risks—including amyloid-related imaging abnormalities and infusion reactions—serious adverse events remain uncommon, and minor side effects are often temporary. If you or a family member has been diagnosed with mild cognitive impairment or early-stage Alzheimer’s disease with confirmed amyloid pathology, discussing lecanemab with a neurologist or dementia specialist is worth considering. The safety data now supports that for appropriate candidates, this treatment offers a reasonable risk-benefit profile with the potential to significantly slow cognitive decline over years. The decision should account for individual factors including disease stage, access to regular infusions, overall health, and personal preferences about medical intervention.
